Bengaluru based biotech startup Zumutor Biologics raises $6.2 million

• ByTejika Bajaj     |    December 10, 2021

The Bengaluru based biotech startup Zumutor Biologics recently announced that it has raised $6.2 million in a funding round led by Siana Capital. The round also saw keen participation from existing investors Accel and Bharat Innovation.

This announcement comes at a time when the biotech startup was all geared up to send its antibody molecule for prostate cancer for its phase 1 trial. With the latest round of funding, the new age company has raised a total of $27 million till date.

Talking about the recent funding round and the subsequent plans of the startup, the CEO of Zumutor Biologics, Kavitha Iyer Rodrigues said, “With this funding, we’re now going to go into investigative new drug finding in the beginning of next year and phase 1 clinical trial in the middle of next year. The company is in a good position now with data from non-human trials looking promising. We will continue to develop other assets in our pipeline, of which there are four, and we will take the asset from phase 1 into phase 2 and look for licensing partners, and at that point might also consider listing.”

Zumutor Biologics is a biotech startup in the immuno-oncology space which creates antibody molecules through its proprietary antibody discovery platform, INABLR. Zumutor’s ZM008 is a first-in-class antibody molecule that it says activates the natural killer (NK) cells in a patient’s body to fight off the cancer cells. With the completion of phase 1 trials, the startup would be able to avail a lot of options in terms of strategic licensing of its lead asset as well as attract collaborations. 

Follow Startup Story